Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Rheumatology and Autoimmunity is Scopus-indexed (Q3, CiteScore 2.3), WoS ESCI, DOAJ. Published by John Wiley and Sons Inc.
Checked against the index lists dated .
ISSN 2767-1410Verify ISSN ↗2767-1429Verify ISSN ↗
Publisher: John Wiley and Sons Inc
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Internal Medicine | 101 / 179 | 43rd | Q3 |
| Rheumatology | 53 / 77 | 31st | Q3 |
| Immunology and Allergy | 172 / 234 | 26th | Q3 |
| Immunology | 187 / 243 | 23rd | Q4 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2021–present, best quartile Q3, CiteScore 2.3.
Rheumatology and Autoimmunity is Q3 in Internal Medicine (rank 101 of 179), Q3 in Rheumatology (rank 53 of 77) and Q3 in Immunology and Allergy (rank 172 of 234), by CiteScore 2025. It is ranked in 4 subject areas in all.
Rheumatology and Autoimmunity is indexed in the Emerging Sources Citation Index, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 2.3, which places it in quartile Q3 at the 43rd percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.495, quartile Q3, with an H-index of 8.
The publisher lists an article processing charge of about US$3,000 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Rheumatology and Autoimmunity is published by John Wiley and Sons Inc. Its print ISSN is 2767-1410 and its online ISSN is 2767-1429.
Yes — indexed in the Emerging Sources Citation Index.
Yes — it is an open-access journal, listed in DOAJ.
Rheumatology and Autoimmunity has an h-index of 12 and a 2-year mean of 1.15 citations per paper (OpenAlex). Its Scopus CiteScore is 2.3, quartile Q3. On 2-year citations it ranks #102 of 172 Scopus journals in Internal Medicine.
Rheumatology and Autoimmunity published 57 papers in 2025; its busiest recent year was 2024 with 59. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 96 research articles (2024–2026), authors are most often from China (63.5%), India (6.8%) and United States (4.3%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.